当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-11-15 , DOI: 10.1016/s1470-2045(24)00580-1 Giovanni Randon MD, Sara Lonardi MD, Prof Matteo Fassan MD, Federica Palermo BS, Stefano Tamberi MD, Elisa Giommoni MD PhD, Carlotta Ceccon BS, Samantha Di Donato MD PhD, Lorenzo Fornaro MD, Oronzo Brunetti MD, Ferdinando De Vita MD, Alessandro Bittoni MD, Claudio Chini MD, Andrea Spallanzani MD PhD, Floriana Nappo MD, Valerie Bethaz MD, Antonia Strippoli MD, Tiziana Latiano MD, Giovanni Gerardo Cardellino MD, Francesco Giuliani MD, Federica Morano MD, Monica Niger MD, Alessandra Raimondi MD, Michele Prisciandaro MD PhD, Chiara Carlotta Pircher MD, Carolina Sciortino MD, Silvia Marchesi MD, Silvio Ken Garattini MD, Giulia Airò MD, Rosalba Miceli BS PhD, Maria Di Bartolomeo MD, Filippo Pietrantonio MD
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-11-15 , DOI: 10.1016/s1470-2045(24)00580-1 Giovanni Randon MD, Sara Lonardi MD, Prof Matteo Fassan MD, Federica Palermo BS, Stefano Tamberi MD, Elisa Giommoni MD PhD, Carlotta Ceccon BS, Samantha Di Donato MD PhD, Lorenzo Fornaro MD, Oronzo Brunetti MD, Ferdinando De Vita MD, Alessandro Bittoni MD, Claudio Chini MD, Andrea Spallanzani MD PhD, Floriana Nappo MD, Valerie Bethaz MD, Antonia Strippoli MD, Tiziana Latiano MD, Giovanni Gerardo Cardellino MD, Francesco Giuliani MD, Federica Morano MD, Monica Niger MD, Alessandra Raimondi MD, Michele Prisciandaro MD PhD, Chiara Carlotta Pircher MD, Carolina Sciortino MD, Silvia Marchesi MD, Silvio Ken Garattini MD, Giulia Airò MD, Rosalba Miceli BS PhD, Maria Di Bartolomeo MD, Filippo Pietrantonio MD
Paclitaxel plus ramucirumab is recommended as a second-line treatment regimen in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer. We aimed to assess whether switch maintenance or early second-line therapy with paclitaxel plus ramucirumab improved outcomes compared with continuation of oxaliplatin and fluoropyrimidine doublet chemotherapy as a first-line strategy.
中文翻译：
雷莫芦单抗联合紫杉醇作为晚期 HER2 阴性胃癌或胃食管结合部癌 （ARMANI） 患者一线奥沙利铂化疗的转换维持与继续治疗：一项随机、开放标签、多中心、3 期试验
紫杉醇加雷莫芦单抗被推荐作为晚期 HER2 阴性胃癌或胃食管结合部癌患者的二线治疗方案。我们旨在评估与继续奥沙利铂和氟嘧啶双药化疗作为一线策略相比，紫杉醇加雷莫芦单抗的转换维持或早期二线治疗是否改善了结局。
更新日期：2024-11-15
中文翻译：
雷莫芦单抗联合紫杉醇作为晚期 HER2 阴性胃癌或胃食管结合部癌 （ARMANI） 患者一线奥沙利铂化疗的转换维持与继续治疗：一项随机、开放标签、多中心、3 期试验
紫杉醇加雷莫芦单抗被推荐作为晚期 HER2 阴性胃癌或胃食管结合部癌患者的二线治疗方案。我们旨在评估与继续奥沙利铂和氟嘧啶双药化疗作为一线策略相比，紫杉醇加雷莫芦单抗的转换维持或早期二线治疗是否改善了结局。
京公网安备 11010802027423号